检索结果-南通市图书馆

R0 Liver Resection should be a First-line Treatment for Selected Patients with Intermediate Hepatocellular Cancer

Journal of Clinical and Translational Hepatology 2023年第4期11卷 757-760页

作者： martin janicko Sylvia Drazilova Peter Jarcuska Second Department of Internal Medicine PJ Safarik UniversityFaculty of Medicine and Pasteur University HospitalKosiceSlovakia

Introduction Hepatocellular cancer(HCC)is the sixth most common malignancy worldwide and the second most common cause of mortality among all *** HCCs occur in cirrhotic livers,but an increasing proportion of cases occur in livers without cirrhosis,particularly in Hepatitis B virus infection or in nonalcoholic fatty liver disease patients.^(1) Liver resection(LR)is the treatment of choice in most noncirrhotic patients,therefore most discussion is related to patients with *** survival(OS)depends on the stage at the time of *** Clinic Liver Cancer(BCLC)staging is the currently preferred staging system for HCC in Europe and North America^(2) Only a small proportion of patients with HCC are diagnosed at a very early or early stage(BCLC 0-A)when curative treatment,including LR,is generally recommended.

关键词： Liver Cancer mortality

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pleiotropic effects of statins in the diseases of the liver

引用

World Journal of Gastroenterology 2016年第27期22卷 6201-6213页

作者： martin janicko Sylvia Drazilova Daniel Pella Jan Fedacko Peter Jarcuska 1~(st) Department of Internal medicine Pavol Jozef Safarik University in Kosice Louis Pasteur University hospital Department of Internal Medicine Hospital Poprad

Statins are a class of molecules that inhibit HMG Co A reductase. They are usually prescribed as a lipid lowering medication. However, there is accumulating evidence that statins have multiple secondary effects both related and unrelated to their lipid-lowering effect. This narrative review of the literature aims to provide the reader with information from clinical studies related to the effect of statin and statins' potential use in patients with liver diseases. In patients with advanced liver disease due to any etiology, statins exhibit an antifibrotic effect possibly through the prevention of hepatic sinusoidal microthrombosis. Two randomized controlled trials confirmed that statins decrease hepatic vein pressure gradient in patients with portal hypertension and improve the survival of patients after variceal bleeding. Lower rates of infections were observed in patients with cirrhosis who received statin treatment. Statins decrease the risk of hepatocellular carcinoma(HCC) in patients with advanced liver disease in general but particularly in patients with chronic hepatitis B and C. Statins in patients with chronic hepatitis C likely increase the virological response to the treatment with pegylated interferon and ribavirin and have the potential to decrease the rate of fibrosis. Finally, data from randomized controlled trials also confirmed that the addition of statin prolongs the survival of patients with advanced HCC even more than sorafenib. Statins are a very promising group of drugs especially in patients with liver disease, where therapeutic options can often be limited. Some indications, such as the prevention of re-bleeding from esophageal varices and the palliative treatment of HCC have been proven through randomized controlled trials, while additional indications still need to be confirmed through prospective studies.

关键词： Statins Hepatitis Cirrhosis Esophageal varices Hepatocellular carcinoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Association between hepatitis B and metabolic syndrome:Current state of the art

引用

World Journal of Gastroenterology 2016年第1期22卷 155-164页

作者： Peter Jarcuska Sylvia Drazilova Jan Fedacko Daniel Pella martin janicko 1st Department of Internal Medicine University Hospital and Pavol Jozef Šafárik University in Kosice04001 KošiceSlovakia Department of Internal Medicine Hospital Poprad A.S.05845 PopradSlovakia

Chronic hepatitis B(CHB)is a global health issue that increases the risk of liver cirrhosis and hepatocellular carcinoma in infected *** syndrome(Met S)is a disease endemic mostly to the developed *** is associated with high cardiovascular mortality and morbidity,diabetes mellitus as well as *** this manuscript,we systematically review the published data on the relationship between Met S and CHB *** studies have described highly variable correlations between CHB on one hand and Met S,non-alcoholic fatty liver disease and dyslipidemia on the *** association between CHB and diabetes mellitus or atherosclerosis has been described as of *** presence of Met S in patients infected with hepatitis B virus increases the risk of fibrosis,cirrhosis and hepatocellular *** lifestyle,but also pharmacological interventions are needed to prevent the development of these complications.

关键词： Hepatitis B Nonalcoholic fatty liver disease Fibrosis Cirrhosis Metabolic syndrome Hepatocellularcarcinoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：